BİR EĞİTİM VE ARAŞTIRMA HASTANESİNDE COVİD-19 ENFEKSİYONU NEDENİ İLE İMMÜN PLAZMA UYGULANAN HASTALARIN DEĞERLENDİRİLMESİ

Amaç COVID-19 enfeksiyonu tedavisi için immün plazma uygulanan hastaların demografik ve klinik verilerinin ve immün plazma transfüzyonu ile ilişkili reaksiyonların değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem Etik kurul onayı alınılan çalışma, retrospektif ve tanımlayıcı bir araştırmadır. 2020 yılında COVİD-19 enfeksiyonu nedeniyle immün plazma uygulanan 130 hasta çalışmaya dahil edildi. Hastaların dosyaları ve transfüzyon merkezi sisteminde kayıtlı olan bilgileri değerlendirilerek araştırmacılar tarafından SPSS paket programı kullanılarak analiz edildi. Bulgular İmmün plazma klinik uygulama kriterlerini sağlayan 130 hastaya 154 kez immün plazma transfüzyon uygulaması yapıldı. Hastaların bir ya da birden fazla kötü prognostik ölçüte sahip, orta ve ağır pnömoni hastaları olduğu, ortalama 17,9 gün hastanede yatarak tedavi gördüğü, %35,4’ünde sürecin ölümle sonuçlandığı belirlendi. İmmun plazma transfüzyon reaksiyonu sıklığı %1,95 olarak saptandı. Anti - A antikoruna sahip hastalarda %23,1’inde sürecin ölümle sonuçlandığı belirlendi. Sonuç İmmün plazma uygulanan bir veya daha fazla kötü prognostik kritere sahip orta ve şiddetli pnömonili hastalar hakkında veri sağlanmasının literatüre katkıda bulunabileceği düşünülmektedir.

EVALUATION OF PATIENTS WHO RECEIVED IMMUNE PLASMA DUE TO COVID-19 INFECTION IN AN EDUCATIONAL AND RESEARCH HOSPITAL

Objective It is aimed to evaluate the demographic and clinical data of patients receiving immune plasma for the treatment of COVID-19 infection and reactions associated with uygulamaimmune plasma transfusion. Materials and Methods The study, which received the approval of the ethics committee, is a retrospective and descriptive study. In 2020, 130 patients who were administered immune plasma due to COVID-19 infection were included in the study. The patients' files and information stored in the transfusion center system were evaluated and analyzed by the researchers using the SPSS package program. Results Immune plasma transfusion was performed 154 times in 130 patients who met the criteria for clinical application of immune plasma. It was determined that the patients had moderate and severe pneumonia with one or more poor prognostic criteria, were hospitalized for an average of 17.9 days, and the process resulted in death in 35.4% of them. The frequency of immune plasma transfusion reaction was found to be 1.95%. It was determined that the process resulted in death in 23.1% of patients with anti - A antibody. Conclusion It is thought that the provision of data on patients with moderate and severe pneumonia with one or more poor prognostic criteria undergoing immune plasma may contribute to the literature.

PDF

___

1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS ‐ CoV ‐ 2 and COVİD 19. Nat Rev Microbiol. 2021;19(3):141-54.
2. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVİD 19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490-6.
3. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVİD 19 With Convalescent Plasma. JAMA. 2020;323(16):1582-9.
4. T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü Kan ve Kan Ürünleri Dairesi Başkanlığı COVİD 19 İmmün (Konvalesan) Plazma Tedarik Ve Klinik Kullanım Rehberi, [cited 12 Apr 2020]. Available at: https://dosyamerkez.saglik.gov.tr/Eklenti/37163,COVİD 19-immun-plazma-rehberi-12-nisan-2020-sonv1-ti-neopdfpdf.pdf?0
5. T.C. Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü, Ağır Pnömoni, ARDS, Sepsis Ve Septik Şok Yönetimi. [cited 27 May 2021]. Available at: https://covid19.saglik.gov.tr/Eklenti/40781/0/COVİD 19rehberiagirpnomoniardssepsisveseptiksokyontemipdf.pdf
6. T.C. Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü, Erişkin Hasta Tedavisi, [cited 7 May 2021]. Available at: https://covid19.saglik.gov.tr/Eklenti/40719/0/COVİD 19rehberieriskinhastayonetimivetedavipdf.pdf
7. Eren C, İstanbul İlinde ABO ve Rh Kan Grupları Dağılımının Analizi. Dicle Med J. 2019;46 (2): 241-6.
8. Casadevall A, Pirofski LA. The convalescent sera option for containing COVİD 19. J Clin Invest. 2020;130(4):1545-8.
9. Joyner M.J., Senefeld J.W., Klassen S.A. Effect of convalescent plasma on mortality among hospitalized patients with COVİD 19: initial three-month experience. [cited 12 August 2020]. Available at: https://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1
10. Pau AK, Aberg J, Baker J, Belperio PS, Coopersmith C, Crew P, et al. Convalescent Plasma for the Treatment of COVİD 19: Perspectives of the National Institutes of Health COVİD 19 Treatment Guidelines Panel. Ann Intern Med. 2021;174(1):93-5.
11. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.Clin Infect Dis. 2011;52(4):447–56.
12. Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM et al. Evaluation of convalescent whole blood for treating Ebola virus disease in Freetown, Sierra Leone. J Infect. 2017;74(3):302–9.
13. Wu XX, Gao HN, Wu HB, Peng XM, Ou HL, Li LJ. Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. Int J Infect Dis. 2015;41:3–5.
14. Zhang JS, Chen JT, Liu YX, Zhang ZS, Gao H, Liu Y, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol. 2005;77(2):147-50.
15. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44-6.
16. FDA. Emergency Use Authorization (EUA) of COVİD 19 Convalescent Plasma for treatment of COVİD 19 in Hospitalized Patients. [cited 2 Feb 2021]. Available at: www.fda.gov/media/141479/download. Available at: https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-COVİD 19-treatment
17. Rizk JG, Forthal DN, Kalantar-Zadeh K, Mehra MR, Lavie CJ, et al. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVİD 19 pandemic. Drug Discov Today. 2021;26(2):593-603.
18. Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVİD 19: Systematic review. J Med Virol. 2020;92(9):1475-83.
19. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVİD 19 patients in Wuhan, China. J Med Virol. 2020;92(10):1890-901.
20. Lindemann M, Lenz V, Knop D, Klump H, Alt M, Aufderhorst UW, et al. Convalescent plasma treatment of critically ill intensive care COVİD 19 patients. Transfusion. 2021;61(5):1394-403.
21. Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al. Treatment of Coronavirus Disease 2019 (COVİD 19) Patients with Convalescent Plasma. Am J Pathol. 2020;190(8):1680-90.
22. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. The feasibility of convalescent plasma therapy in severe COVİD 19 patients: a pilot study. [cited 23 March 2020]. Available at: https://www.medrxiv.org/content/10.1101/2020.03.16.20036145v1.full-text
23. Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z, et al. Epidemiological, comorbidity factors with severity and prognosis of COVİD 19: a systematic review and meta-analysis. Aging (Albany NY). 2020 ;12(13):12493-503.
24. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVİD 19. Lancet. 2020;395(10229):1014-5.
25. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender Differences in Patients With COVİD 19: Focus on Severity and Mortality. Front Public Health. 2020;8:152.
26. Pan F, Yang L, Li Y, Liang B, Li L, Ye T, et al. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVİD 19): a case-control study. Int J Med Sci. 2020;17(9):1281-92.
27. Wu Y, Feng Z, Li P, Yu Q. Relationship between ABO blood group distribution and clinical characteristics in patients with COVİD 19. Clin Chim Acta. 2020 ;509:220-3.
28. Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Relationship between the ABO Blood Group and the COVİD 19 Susceptibility. Clin Infect Dis. 2021;73(2):328-31.
29. Wu BB, Gu DZ, Yu JN, Yang J, Shen WQ. Association between ABO blood groups and COVİD 19 infection, severity and demise: A systematic review and meta-analysis. Infect Genet Evol. 2020 ;84:104485.
30. Gérard C, Maggipinto G, Minon JM. COVİD 19 and ABO blood group: another viewpoint. Br J Haematol. 2020;190(2):93-4.
31. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from COVİD 19. N Engl J Med. 2021;384(11):1015-27.
32. Gajic O, Rana R, Winters JL, Yılmaz M, Mendez JL, Rickman OB, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med. 2007;176(9):886-91.
33. Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. Randomized Trial of Convalescent Plasma in COVİD 19 Severe Pneumonia. N Engl J Med. 2021;384(7):619-29.
34. Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al. The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVİD 19: Systematic Review and Meta-analysis. Mayo Clin Proc. 2021;96(5):1262-75.
35. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS ‐ CoV ‐ 2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81.
36. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. COVİD 19 Lombardy ICU Network. Risk Factors Associated With Mortality Among Patients With COVİD 19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345-55.